Information for the public
Lebrikizumab (Ebglyss) is available on the NHS. It is a possible treatment for moderate to severe atopic dermatitis (eczema) in people 12 years and over who weigh 40 kg or more:
- when systemic treatment is suitable, and
- at least 1 systemic immunosuppressant has not worked or these treatments are not suitable, and
- dupilumab or tralokinumab would otherwise be used.
Systemic treatments work throughout the whole body. They can include injections, infusions or medicines taken by mouth. Lebrikizumab is given by injection.
If your atopic dermatitis does not improve enough, lebrikizumab will be stopped after 16 weeks. When assessing how much it has improved, healthcare professionals should take into account how the atopic dermatitis may look on your skin colour.
When assessing how atopic dermatitis affects your quality of life, healthcare professionals should take into account any disabilities or difficulties in communicating you might have.
If you are not eligible for lebrikizumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
The NHS webpage on atopic eczema (atopic dermatitis) may be a good place to find out more.
These organisations can give you advice and support:
- Eczema Outreach Support, 01506 840395
- National Eczema Society, 020 7281 3553
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
ISBN: 978-1-4731-6207-5
This page was last updated: